The sildenafil NO–cGMP pathway is a signaling sequence in which nitric oxide activates soluble guanylate cyclase, guanylate cyclase converts GTP into cyclic GMP, cGMP activates downstream effectors such as protein kinase G, and PDE5 limits the signal by breaking cGMP down.
Sildenafil enters this sequence at the PDE5 step. It does not generate nitric oxide, directly activate guanylate cyclase or create cGMP. Instead, PDE5 inhibition reduces cGMP degradation and allows an already activated NO–cGMP signal to persist more strongly.
This page follows that pathway step by step. The molecular interaction between sildenafil and PDE5 is treated separately on the sildenafil PDE5 inhibition page, while the connection between target engagement, exposure and biological response belongs on the sildenafil pharmacodynamics page.
The NO–cGMP pathway links an upstream nitric oxide signal to changes in smooth-muscle tone. Nitric oxide activates soluble guanylate cyclase inside target cells, increasing production of cGMP from GTP.
cGMP then acts as a second messenger. One of its major downstream effectors is cGMP-dependent protein kinase, commonly called protein kinase G or PKG, which modifies proteins involved in calcium handling and contractile regulation.
PDE5 provides an opposing regulatory step by hydrolyzing cGMP to 5′-GMP. Sildenafil inhibits this breakdown step, shifting the balance toward greater persistence of cGMP signaling when the pathway has already been activated.
| Pathway Component | Primary Role |
|---|---|
| Nitric oxide (NO) | Upstream signaling molecule |
| Soluble guanylate cyclase (sGC) | Converts GTP into cGMP after NO activation |
| cGMP | Intracellular second messenger |
| Protein kinase G (PKG) | Major cGMP-regulated downstream effector |
| PDE5 | Hydrolyzes cGMP and limits signal persistence |
| Sildenafil | Inhibits PDE5-mediated cGMP degradation |
Nitric oxide is the upstream signal that activates the classical NO–cGMP pathway. In erectile tissue, neuronal and endothelial sources contribute NO, with sexual stimulation producing local nitric oxide release in the corpus cavernosum.
Nitric oxide is synthesized from L-arginine by nitric oxide synthase enzymes. Neuronal NOS and endothelial NOS are particularly relevant to cavernosal signaling, although the relative contribution of different cellular sources depends on physiological context.
This upstream requirement explains an important feature of sildenafil pharmacology: sildenafil does not substitute for nitric oxide. It acts farther downstream and enhances cGMP signaling after the pathway has been activated.
| Signal Component | Position in Pathway |
|---|---|
| L-arginine | Substrate used by nitric oxide synthase |
| Nitric oxide synthase | Generates NO |
| Nitric oxide | Diffusible upstream signaling molecule |
| Sildenafil | Does not directly generate NO |
After nitric oxide reaches a responsive smooth-muscle cell, it activates soluble guanylate cyclase. This enzyme is the key biochemical bridge between the NO signal and production of cGMP.
Activated soluble guanylate cyclase catalyzes conversion of guanosine triphosphate, or GTP, into cyclic guanosine monophosphate, or cGMP.
The intracellular cGMP concentration at any moment therefore reflects both production through guanylate cyclase and removal through phosphodiesterases such as PDE5.
| Process | Pathway Function |
|---|---|
| NO binds / activates sGC | Switches on cGMP synthesis |
| GTP | Substrate for guanylate cyclase |
| GTP → cGMP | Produces the second messenger |
| cGMP concentration | Reflects the balance between synthesis and degradation |
cGMP is not simply an intermediate molecule between guanylate cyclase and PDE5. It functions as an intracellular second messenger that activates several cGMP-sensitive targets.
A major downstream target in smooth muscle is cGMP-dependent protein kinase, or PKG. Activated PKG phosphorylates proteins involved in ion transport, intracellular calcium handling and regulation of the contractile machinery.
The overall downstream direction is reduced intracellular calcium availability and reduced contractile signaling, favoring smooth-muscle relaxation. Other cGMP-regulated targets, including ion channels and phosphodiesterases, also contribute to pathway regulation.
| cGMP Target / Effect | Pathway Role |
|---|---|
| Protein kinase G (PKG) | Major cGMP-dependent protein kinase |
| Ion channels and pumps | Participate in regulation of membrane potential and calcium handling |
| Intracellular Ca²⁺ | Generally reduced through downstream NO–cGMP signaling |
| Contractile signaling | Reduced as smooth-muscle relaxation is favored |
PDE5 is a cGMP-specific phosphodiesterase that helps terminate the NO–cGMP signal by hydrolyzing cGMP to 5′-GMP.
This degradation step prevents cGMP generated after an upstream signal from remaining elevated indefinitely. PDE5 therefore acts as a regulator of signal magnitude and duration rather than as the source of the signal.
Sildenafil inhibits the catalytic activity of PDE5, decreasing cGMP breakdown. The enzyme-level interaction is examined in greater detail on the sildenafil PDE5 inhibition page.
| Component | Function |
|---|---|
| PDE5 | cGMP-specific phosphodiesterase |
| Substrate | cGMP |
| Hydrolysis product | 5′-GMP |
| Normal PDE5 activity | Limits cGMP signal magnitude and duration |
| PDE5 inhibition | Reduces enzymatic cGMP degradation |
Sildenafil acts downstream of nitric oxide generation and cGMP synthesis. Its primary molecular target is PDE5, not nitric oxide synthase or guanylate cyclase.
By inhibiting PDE5, sildenafil reduces the rate at which existing cGMP is degraded. This allows cGMP generated in response to upstream NO signaling to reach higher or more persistent intracellular levels than it would with uninhibited PDE5 activity.
Current ED labeling emphasizes this dependence on upstream activation: sildenafil has no direct relaxant effect on isolated human corpus cavernosum and, at recommended doses, does not produce the expected erectile response in the absence of sexual stimulation.
| Pathway Stage | Direct Sildenafil Action? |
|---|---|
| Nitric oxide synthesis | No |
| Soluble guanylate cyclase activation | No |
| cGMP synthesis from GTP | No |
| PDE5 catalytic activity | Yes — inhibited |
| cGMP degradation | Reduced indirectly through PDE5 inhibition |
| Smooth-muscle signaling | Modified downstream through greater cGMP persistence |
The effect of sildenafil is best described as enhancement or preservation of an endogenous cGMP signal rather than independent creation of a new signal.
Before PDE5 inhibition, cGMP concentration reflects continuous competition between guanylate-cyclase-mediated formation and phosphodiesterase-mediated degradation. Reducing PDE5 activity changes that balance by slowing one of the principal cGMP removal pathways.
The result is greater persistence of cGMP-dependent signaling while upstream NO signaling is present. This explains why describing sildenafil simply as a general vasodilator misses the pathway dependence of its mechanism.
| Condition | Effect on cGMP |
|---|---|
| NO signal absent or minimal | Limited upstream cGMP generation |
| NO activates sGC | cGMP production increases |
| Normal PDE5 activity | cGMP is continuously degraded |
| Sildenafil inhibits PDE5 | cGMP degradation slows |
| Net pathway effect | Endogenous cGMP signal persists more strongly |
cGMP-dependent signaling promotes smooth-muscle relaxation through several linked cellular mechanisms rather than through one isolated molecular event.
PKG activation alters proteins involved in calcium entry, calcium storage and calcium sensitivity of the contractile apparatus. The overall effect is a reduction in intracellular calcium-dependent contractile signaling.
In corpus cavernosum smooth muscle, relaxation facilitates increased arterial inflow during the physiological erectile response. In pulmonary vascular smooth muscle, increased cGMP promotes relaxation and vasodilation. These tissue-level consequences are downstream of the same central PDE5–cGMP mechanism.
| Pathway Level | Downstream Event |
|---|---|
| cGMP | Activates cGMP-regulated effectors including PKG |
| PKG signaling | Modifies calcium handling and contractile regulation |
| Intracellular calcium / calcium sensitivity | Reduced overall contractile drive |
| Smooth muscle | Relaxation |
| Corpus cavernosum | Facilitates increased blood inflow during physiological activation |
| Pulmonary vasculature | Produces vascular relaxation and vasodilation |
The NO–cGMP pathway and PDE5 inhibition describe different levels of the same mechanism. The pathway explains how a signal moves from nitric oxide through cGMP to downstream cellular effects, whereas target inhibition describes sildenafil's interaction with one regulatory enzyme.
A PDE5-focused page therefore answers questions such as enzyme selectivity, binding and target specificity. This page instead explains how that target sits between cGMP production and cGMP-dependent smooth-muscle signaling.
Pharmacodynamics is broader still because it connects target engagement and signaling changes with measurable biological or clinical responses.
| Topic | Primary Question | Dedicated Resource |
|---|---|---|
| PDE5 inhibition | What enzyme does sildenafil inhibit and how? | Sildenafil PDE5 Inhibition |
| NO–cGMP pathway | How does the biological signal flow? | Current page |
| Pharmacodynamics | How does target engagement relate to biological response? | Sildenafil Pharmacodynamics |
Pharmacokinetics and the NO–cGMP pathway answer different questions. Pharmacokinetics describes sildenafil concentrations across time, while this pathway describes what sildenafil can do when sufficient drug reaches PDE5.
The amount of sildenafil available at a target influences the extent of PDE5 inhibition, but concentration alone does not create the upstream NO signal. Conversely, an active NO–cGMP pathway does not determine the plasma concentration of sildenafil.
The bridge between exposure and biological effect is the PK–PD relationship. That integrative interpretation belongs primarily on the sildenafil pharmacodynamics page and the exposure-focused PK resources.
| Domain | Question |
|---|---|
| Pharmacokinetics | How does sildenafil concentration change across time? |
| Target engagement | How much PDE5 inhibition occurs at a given exposure? |
| NO–cGMP pathway | How is an upstream NO signal translated and regulated? |
| Pharmacodynamics | How do target and pathway changes relate to biological response? |
The NO–cGMP system operates in many tissues, so the same second messenger does not produce one universal physiological outcome. Response depends on where PDE5 is expressed, which downstream targets are present and what upstream signals are active.
In ED-oriented labeling, the pathway is described in corpus cavernosum smooth muscle, where NO released during sexual stimulation increases cGMP and promotes relaxation. In PAH-oriented labeling, PDE5 inhibition increases cGMP within pulmonary vascular smooth muscle and promotes pulmonary vasodilation.
The common mechanism is PDE5-regulated cGMP signaling, while the tissue context determines the physiological consequence. This distinction prevents a pathway diagram from being treated as a complete prediction of clinical response.
| Tissue Context | NO–cGMP / PDE5 Relevance |
|---|---|
| Corpus cavernosum | cGMP-mediated smooth-muscle relaxation supports increased blood inflow |
| Pulmonary vascular smooth muscle | Higher cGMP promotes vascular relaxation and pulmonary vasodilation |
| Other vascular tissues | PDE5 inhibition can also influence systemic vascular tone |
| Key principle | Same core signaling pathway, tissue-specific physiological outcome |
N-desmethyl sildenafil is the major circulating active sildenafil metabolite and retains activity at PDE5. It therefore participates in the same broad cGMP-regulatory mechanism as the parent drug.
Current labeling reports that its in-vitro PDE5 potency is approximately 50% that of parent sildenafil, while its plasma concentrations in healthy volunteers are approximately 40% of parent concentrations.
Those properties mean metabolite exposure contributes to overall PDE5-inhibitory pharmacology, but this pathway page does not treat parent and metabolite concentration-time profiles in detail. That topic remains on the sildenafil active metabolite page.
| Component | Pathway Relevance |
|---|---|
| Parent sildenafil | Primary administered PDE5 inhibitor |
| N-desmethyl sildenafil | Circulating active metabolite with PDE5 activity |
| Relative in-vitro potency | Approximately 50% of parent sildenafil |
| Primary shared pathway effect | Reduced PDE5-mediated cGMP degradation |
| Detailed metabolite resource | Sildenafil Active Metabolite |
The pathway can be read as a directional sequence: nitric oxide activates soluble guanylate cyclase, guanylate cyclase converts GTP to cGMP, cGMP activates downstream effectors including PKG, and those signals reduce smooth-muscle contractile activity.
PDE5 limits this signal by hydrolyzing cGMP to 5′-GMP. Sildenafil inhibits PDE5, slowing cGMP degradation and enhancing the persistence of an NO-driven signal.
The key interpretive point is that sildenafil modifies signal termination rather than initiating the pathway. That distinction explains both its dependence on upstream NO signaling and why excessive cGMP-related signaling can become clinically important when sildenafil is combined with nitric oxide donors such as nitrates.
| Step | Pathway Event |
|---|---|
| 1 | Nitric oxide is generated and released |
| 2 | NO activates soluble guanylate cyclase |
| 3 | Guanylate cyclase converts GTP to cGMP |
| 4 | cGMP activates downstream effectors including PKG |
| 5 | Calcium-dependent contractile signaling decreases |
| 6 | Smooth muscle relaxes |
| 7 | PDE5 hydrolyzes cGMP and limits the signal |
| 8 | Sildenafil inhibits PDE5 and slows cGMP breakdown |
It is the signaling sequence in which nitric oxide activates soluble guanylate cyclase, guanylate cyclase generates cGMP from GTP, cGMP activates downstream effectors such as PKG, and PDE5 limits the signal by degrading cGMP. Sildenafil acts by inhibiting PDE5.
No. Sildenafil does not directly create nitric oxide or synthesize cGMP. It inhibits PDE5, which slows degradation of cGMP that has already been generated through upstream NO–guanylate-cyclase signaling.
cGMP activates downstream targets including protein kinase G. These signals regulate ion transport, intracellular calcium and contractile proteins, shifting smooth muscle toward relaxation.
PDE5 hydrolyzes cGMP to 5′-GMP, helping terminate or limit cGMP signaling. Sildenafil inhibits this PDE5-mediated degradation step.
Sexual stimulation causes local nitric oxide release in the corpus cavernosum. Sildenafil acts downstream by preserving cGMP generated from that NO signal; it does not independently initiate the upstream signal.
No. The same central PDE5–cGMP mechanism is relevant in pulmonary vascular smooth muscle. In PAH, sildenafil increases cGMP within pulmonary vascular smooth muscle and promotes vasodilation.